Overview

A Study to Assess Relatlimab in Combination With Nivolumab in Chinese Participants With Advanced Solid Tumors

Status:
Not yet recruiting
Trial end date:
2024-10-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, drug levels, immunogenicity and preliminary efficacy of BMS-986213 (relatlimab/nivolumab fixed-dose combination) in Chinese participants with advanced solid tumors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb